Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/34500300http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/34500300http://www.w3.org/2000/01/rdf-schema#comment"

Background

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a significant pathogenic factor in Down syndrome (DS), wherein DYRK1A is overexpressed by 1.5-fold because of trisomy of human chromosome 21. Thus, DYRK1A inhibition is considered a therapeutic strategy to modify the disease.

Purpose

This study aims to identify a novel DYRK1A inhibitor and validate its therapeutic potential in DS-related pathological conditions.

Study design

In order to identify a novel DYRK1A inhibitor, we carried out two-step screening: a structure-based virtual screening of > 300,000 chemical library (first step) and cell-based nuclear factor of activated T-cells (NFAT)-response element (RE) promoter assay (second step). Primary hits were evaluated for their DYRK1A inhibitory activity using in vitro kinase assay and Tau phosphorylation in mammalian cells. Confirmed hit was further evaluated in pathological conditions including DYRK1A-overexpressing fibroblasts, flies, and mice.

Results

We identified aristolactam BIII, a natural product derived from herbal plants, as a novel DYRK1A inhibitor. It potently inhibited the kinase activity of DYRK1A in vitro (IC50 = 9.67 nM) and effectively suppressed DYRK1A-mediated hyperphosphorylation of Tau in mammalian cells. Aristolactam BIII rescued the proliferative defects of DYRK1A transgenic (TG) mouse-derived fibroblasts and neurological and phenotypic defects of DS-like Drosophila models. Oral administration of aristolactam BIII acutely suppressed Tau hyperphosphorylation in the brain of DYRK1A TG mice. In the open field test, aristolactam BIII significantly ameliorated the exploratory behavioral deficit of DYRK1A TG mice.

Conclusion

Our work revealed that aristolactam BIII as a novel DYRK1A inhibitor rescues DS phenotypes in cells and in vivo and suggested its therapeutic potential for the treatment of DYRK1A-related diseases."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.org/dc/terms/identifier"doi:10.1016/j.phymed.2021.153695"xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/author"Kim D."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/author"Lee K.S."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/author"Lee J.Y."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/author"Yang A."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/author"Cho S."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/author"Choi M."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/author"Yoon E."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/author"Han S.B."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/author"Jo M.J."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/author"Ham Y."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/author"Kim A.K."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/author"Heo J.N."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/author"Ki M.H."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/date"2021"xsd:gYear
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/name"Phytomedicine"xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/pages"153695"xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/title"Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes."xsd:string
http://purl.uniprot.org/citations/34500300http://purl.uniprot.org/core/volume"92"xsd:string
http://purl.uniprot.org/citations/34500300http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/34500300
http://purl.uniprot.org/citations/34500300http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/34500300
http://purl.uniprot.org/uniprot/#_P21521-mappedCitation-34500300http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34500300
http://purl.uniprot.org/uniprot/#_P49657-mappedCitation-34500300http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/34500300
▶